DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/pt5xqz/global_hepatitis) has announced the addition of the "Global Hepatitis B Epidemiology and Patient Flow Analysis - 2012" report to their offering.
Fore Pharma announced the results of its Hepatitis B patient population study in a new report Global Hepatitis B Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Hepatitis B epidemiology, Hepatitis B diagnosed patients, and Hepatitis B treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Hepatitis B derived from epidemiological analysis, percentage of patients diagnosed with Hepatitis B, and percentage of patients treated with Hepatitis B therapy.
The study helps executives estimate Hepatitis B market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Hepatitis B prevalence, Hepatitis B diagnosis rate, and Hepatitis B treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.
Key Features of the Report:
- Hepatitis B: Disease Definition
- Hepatitis B Patient Flow
- Hepatitis B Prevalence
- Hepatitis B Diagnosed Patients
- Hepatitis B Treated Patients
For more information visit http://www.researchandmarkets.com/research/pt5xqz/global_hepatitis
Source: Research and Markets